Consensus Foghorn Therapeutics Inc.

Equities

FHTX

US3441741077

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
5.51 ^USD	-5.16%		-0.90%	-14.57%

May. 06	Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 06	North American Morning Briefing : Stock Futures -2-	DJ

Evolution of the average Target Price on Foghorn Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

4956047e91913bc873d6894fea.uTvs53pLN5uyRAwakPE4o3e1YoijMnZXNClLy8rbWSo.7HevtxQfWO3aNWoixpcIjkbFU8PtA0cxYmUYhansb0CBT6PRLw9z48gVaw~3d5ab3c9d47f0cccee17bc57b3824892

Analyst Recommendations on Foghorn Therapeutics Inc.

North American Morning Briefing : Stock Futures -2-	May. 06	DJ
Morgan Stanley Adjusts Price Target on Foghorn Therapeutics to $6 From $10, Maintains Equalweight Rating	Nov. 13	MT
Morgan Stanley Adjusts Price Target on Foghorn Therapeutics to $10 From $13, Maintains Equal-Weight Rating	23-07-06	MT
Goldman Sachs Cuts Foghorn Therapeutics' Price Target to $19 From $21, Keeps Buy Rating	23-06-29	MT
Wedbush Trims Foghorn Therapeutics Price Target to $13 From $14, Maintains Outperform Rating	23-06-28	MT
HC Wainwright Adjusts Price Target on Foghorn Therapeutics to $20 From $25, Keeps Buy Rating	23-05-09	MT
Wedbush Trims Foghorn Therapeutics' Price Target to $14 From $15, Tweaks Financing Assumptions; Keeps Outperform Rating	23-05-09	MT
BMO Capital Adjusts Price Target on Foghorn Therapeutics to $19 From $20, Maintains Outperform Rating	23-04-25	MT
Wedbush Lowers Foghorn Therapeutics' Price Target to $15 From $20 After Pause in Enrollment for FHD-609 Program, Keeps Outperform Rating	23-04-25	MT
BofA Securities Initiates Coverage on Foghorn Therapeutics With Buy Rating, $10 Price Target	23-03-28	MT
Wedbush Lowers Foghorn Therapeutics's Price Target to $20 From $25, Tweaks Timing Around Programs; Keeps Outperform Rating	23-03-10	MT
BMO Capital Starts Foghorn Therapeutics at Outperform With $20 Price Target	23-01-05	MT
Morgan Stanley Adjusts Foghorn Therapeutics Price Target to $14 From $15, Maintains Equal Weight Rating	22-11-21	MT
Morgan Stanley Downgrades Foghorn Therapeutics to Equalweight From Overweight, Lowers Price Target to $15 From $25	22-08-24	MT
ANALYST RECOMMENDATIONS : Intuit, XPeng, Rio Tinto, Prologis, Charter Communications...	22-08-24
Morgan Stanley Downgrades Foghorn Therapeutics to Equalweight From Overweight, Cuts Price Target to $15 From $25	22-08-23	MT
Wedbush Cuts Price Target on Foghorn Therapeutics to $25 From $32, Citing FHD-286 Clinical Hold; Outperform Rating Kept	22-08-23	MT
Wall Street Stabilizes Pre-Bell After Slump Fueled by Rate Hike Concerns	22-08-23	MT
HC Wainwright Increases Foghorn Therapeutics' Price Target to $25 From $18, Maintains Buy Rating	22-08-10	MT
Goldman Sachs Adjusts Foghorn Therapeutics' Price Target to $21 from $30, Keeps Buy Rating	22-05-24	MT
Morgan Stanley Adjusts Price Target for Foghorn Therapeutics to $25 From $26, Maintains Overweight Rating	22-05-23	MT
Wall Street Set for Gains as China Rate Cut Boosts Sentiment	22-05-20	MT
HC Wainwright Adjusts Foghorn Therapeutics' Price Target to $18 From $25, Keeps Buy Rating	22-05-20	MT
Wedbush Adds Outperform-Rated Foghorn Therapeutics to Best Ideas List; Price Target is $32	22-03-11	MT
Morgan Stanley Raises Price Target for Foghorn Therapeutics to $26 From $23, Maintains Overweight Rating	21-12-15	MT